Related Experiment Video
Updated: May 21, 2026
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
Published on: November 5, 2020
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Jordan M Winter1, Charles J Yeo, Jonathan R Brody
1Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. jordan.winter@jefferson.edu
Abstract:
Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens.
